GRAIL, Inc.
GRAIL is a healthcare company dedicated to early cancer detection through innovative technologies like the Galleri® multi-cancer early detection test. Their mission is to detect cancer early, when it can be cured, and to transform cancer screening and care by harnessing genomics and machine learning. They collaborate with leading health systems and academic centers worldwide to bring their groundbreaking technology to patients.
Industries
Nr. of Employees
Very Large (1000+)
GRAIL, Inc.
1525 O’Brien Drive Menlo Park, CA 94025
Patents
Methods of preparing dual-indexed DNA libraries for bisulfite conversion sequencing
US-12264364-B2
View DetailsSystems and methods for using a convolutional neural network to detect contamination
US-12236346-B2
View DetailsSource of origin deconvolution based on methylation fragments in cell-free DNA samples
US-12234514-B2
View DetailsSystems and methods for classifying patients with respect to multiple cancer classes
US-12191000-B2
View Details
Methods of preparing dual-indexed DNA libraries for bisulfite conversion sequencing
US-12264364-B2
View DetailsSystems and methods for using a convolutional neural network to detect contamination
US-12236346-B2
View DetailsSource of origin deconvolution based on methylation fragments in cell-free DNA samples
US-12234514-B2
View DetailsSystems and methods for classifying patients with respect to multiple cancer classes
US-12191000-B2
View DetailsProducts
Multi-cancer early detection blood test (MCED)
A blood-based screening assay that sequences circulating cell-free DNA and applies methylation-targeted analysis and machine learning to detect cancer signals and predict likely tissue-of-origin for positive results; intended to complement recommended single-cancer screening.
Diagnostic aid blood test for symptomatic patients (DAC)
A blood-based diagnostic aid intended to accelerate diagnostic resolution in patients presenting with non-specific signs and symptoms and a clinical suspicion of cancer by detecting cancer-associated methylation signals and suggesting likely cancer location.
Multi-cancer early detection blood test (MCED)
A blood-based screening assay that sequences circulating cell-free DNA and applies methylation-targeted analysis and machine learning to detect cancer signals and predict likely tissue-of-origin for positive results; intended to complement recommended single-cancer screening.
Diagnostic aid blood test for symptomatic patients (DAC)
A blood-based diagnostic aid intended to accelerate diagnostic resolution in patients presenting with non-specific signs and symptoms and a clinical suspicion of cancer by detecting cancer-associated methylation signals and suggesting likely cancer location.
Services
Competitive funding and collaboration program supporting investigator-sponsored trials and research collaborations, including LOI intake, protocol and budget review, contracting, and study start-up packages.
Provision of post-diagnosis, research-use-only blood-based liquid biopsy assays and collaborative programs for biopharma clinical research applications.
Services to streamline test ordering and result delivery by integrating test ordering into provider workflows and health IT platforms.
Competitive funding and collaboration program supporting investigator-sponsored trials and research collaborations, including LOI intake, protocol and budget review, contracting, and study start-up packages.
Provision of post-diagnosis, research-use-only blood-based liquid biopsy assays and collaborative programs for biopharma clinical research applications.
Services to streamline test ordering and result delivery by integrating test ordering into provider workflows and health IT platforms.
Expertise Areas
- Multi-cancer early detection (MCED)
- Cell-free DNA (cfDNA) analysis
- Targeted methylation assay development
- Machine learning for diagnostic classifiers
Key Technologies
- Targeted methylation sequencing
- Cell-free DNA (cfDNA) sequencing
- Next-generation sequencing
- Machine learning classifiers
News & Updates
GRAIL announced positive results from their PATHFINDER 2 study, a key milestone in their clinical development.
GRAIL announced inducement grants to new employees under NASDAQ rules.
GRAIL announced their participation in the Jefferies Healthcare Conference.
GRAIL released their financial results for Q1 2025.
GRAIL supports policy efforts to improve access to multi-cancer early detection.
GRAIL was recognized for its impact on society by Fortune magazine.
GRAIL announced positive results from their PATHFINDER 2 study, a key milestone in their clinical development.
GRAIL announced inducement grants to new employees under NASDAQ rules.
GRAIL announced their participation in the Jefferies Healthcare Conference.
GRAIL released their financial results for Q1 2025.
GRAIL supports policy efforts to improve access to multi-cancer early detection.
GRAIL was recognized for its impact on society by Fortune magazine.